Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 394

1.

Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study.

Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J.

RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.

2.

The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set.

Leung YY, Orbai AM, Ogdie A, Coates LC, de Wit M, Callis Duffin K, Eder L, Gladman DD, Goel N, Mease PJ, Strand V, FitzGerald O, Tillett W.

J Rheumatol Suppl. 2019 Jun;95:33-37. doi: 10.3899/jrheum.190122.

PMID:
31154402
3.

Reply.

Kim AHJ, Strand V, Atkinson JP.

Arthritis Rheumatol. 2019 May 10. doi: 10.1002/art.40923. [Epub ahead of print] No abstract available.

PMID:
31074940
4.

Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials.

Klokker L, Berthelsen DB, Woodworth T, Andersen KM, Furst DE, Devoe D, Williamson PR, Suarez-Almazor ME, Strand V, Leong AL, Goel N, Boers M, Brooks PM, March L, Sloan VS, Tugwell P, Simon LS, Christensen R.

J Rheumatol. 2019 May 1. pii: jrheum.190196. doi: 10.3899/jrheum.190196. [Epub ahead of print]

PMID:
31043547
5.

Control of allergic rhinitis with MP-AzeFlu: a noninterventional study of a Swedish cohort.

Stjarne P, Strand V, Theman K, Ehnhage A.

Rhinology. 2019 Aug 1;57(4):279-286. doi: 10.4193/Rhin18.028.

PMID:
30938376
6.

Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.

Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

BMC Rheumatol. 2018 Feb 12;2:3. doi: 10.1186/s41927-018-0011-1. eCollection 2018.

7.

Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.

Gossec L, Strand V, Proudfoot C, Chen CI, Guillonneau S, Kimura T, van Hoogstraten H, Mangan E, Reaney M.

J Rheumatol. 2019 Mar 15. pii: jrheum.180904. doi: 10.3899/jrheum.180904. [Epub ahead of print]

8.

Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis.

Lopez-Olivo MA, Negrón JB, Zogala RJ, Carmona L, Criner K, Goel N, Gonzalez-Lopez L, Ingegnoli F, Leong A, March L, Shea B, Strand V, Tugwell P, Westrich-Robertson T, Zamora NV, Christensen R, Suarez-Almazor ME.

J Rheumatol. 2019 Mar 1. pii: jrheum.181076. doi: 10.3899/jrheum.181076. [Epub ahead of print]

PMID:
30824644
9.

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis.

Strand V, McInnes I, Mease P, Nash P, Thom H, Kalyvas C, Hunger M, Gandhi K, Pricop L, Jugl S, Choy E.

J Comp Eff Res. 2019 May;8(7):497-510. doi: 10.2217/cer-2018-0141. Epub 2019 Feb 26.

10.

Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.

Strand V, Dimonaco S, Tuckwell K, Klearman M, Collinson N, Stone JH.

Arthritis Res Ther. 2019 Feb 20;21(1):64. doi: 10.1186/s13075-019-1837-7.

11.

Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.

Park EH, Strand V, Oh YJ, Song YW, Lee EB.

Arthritis Res Ther. 2019 Feb 15;21(1):61. doi: 10.1186/s13075-019-1842-x.

12.

Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report.

Duarte-García A, Leung YY, Coates LC, Beaton D, Christensen R, Craig ET, de Wit M, Eder L, Fallon L, FitzGerald O, Gladman DD, Goel N, Holland R, Lindsay C, Maxwell L, Mease P, Orbai AM, Shea B, Strand V, Veale DJ, Tillett W, Ogdie A.

J Rheumatol. 2019 Aug;46(8):996-1005. doi: 10.3899/jrheum.181089. Epub 2019 Feb 15.

PMID:
30770518
13.

OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies.

Boers M, Beaton DE, Shea BJ, Maxwell LJ, Bartlett SJ, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March L, Simon LS, Singh JA, Strand V, Wells GA, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1021-1027. doi: 10.3899/jrheum.181096. Epub 2019 Feb 15.

PMID:
30770515
14.

Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology.

Maxwell LJ, Beaton DE, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit M, Gossec L, March L, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1014-1020. doi: 10.3899/jrheum.181097. Epub 2019 Feb 15.

PMID:
30770502
15.

Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop.

Morgan EM, Munro JE, Horonjeff J, Horgan B, Shea B, Feldman BM, Clairman H, Bingham CO 3rd, Thornhill S, Strand V, Alongi A, Magni-Manzoni S, van Rossum MAJ, Vesely R, Vojinovic J, Brunner HI, Harris JG, Horton DB, Lovell DJ, Mannion M, Rahimi H, Ravelli A, Ringold S, Ruperto N, Schrandt MS, Shenoi S, Shiff NJ, Toupin-April K, Tzaribachev N, Weiss P, Consolaro A.

J Rheumatol. 2019 Aug;46(8):1006-1013. doi: 10.3899/jrheum.181088. Epub 2019 Feb 15.

PMID:
30770499
16.

Unmet needs in psoriatic arthritis patients receiving immunomodulatory therapy: results from a large multinational real-world study.

Alten R, Conaghan PG, Strand V, Sullivan E, Blackburn S, Tian H, Gandhi K, Jugl SM, Deodhar A.

Clin Rheumatol. 2019 Jun;38(6):1615-1626. doi: 10.1007/s10067-019-04446-z. Epub 2019 Feb 4.

PMID:
30719594
17.

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Chen L, Kudlacz E, Wu J, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000808. doi: 10.1136/rmdopen-2018-000808. eCollection 2019.

18.

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA.

RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. eCollection 2019.

19.

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology.

Beaton DE, Maxwell LJ, Shea BJ, Wells GA, Boers M, Grosskleg S, Bingham CO 3rd, Conaghan PG, D'Agostino MA, de Wit MP, Gossec L, March LM, Simon LS, Singh JA, Strand V, Tugwell P.

J Rheumatol. 2019 Aug;46(8):1028-1035. doi: 10.3899/jrheum.181218. Epub 2019 Feb 1.

PMID:
30709952
20.

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.

van der Heijde D, Strand V, Tanaka Y, Keystone E, Kremer J, Zerbini CAF, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Gruben D, Wallenstein G, Connell CA, Fleischmann R; ORAL Scan Investigators.

Arthritis Rheumatol. 2019 Jun;71(6):878-891. doi: 10.1002/art.40803. Epub 2019 Apr 24.

21.

Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies.

Bangert E, Wakani L, Merchant M, Strand V, Touma Z.

Patient Relat Outcome Meas. 2019 Jan 9;10:1-7. doi: 10.2147/PROM.S134326. eCollection 2019. Review.

22.

Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.

Andersen KM, Cheah JTL, March L, Bartlett SJ, Beaton D, Bingham CO 3rd, Brooks PM, Christensen R, Conaghan PG, D'Agostino MA, de Wit M, Dueck AC, Goodman SM, Grosskleg S, Hill CL, Howell M, Mackie SL, Richards B, Shea B, Singh JA, Strand V, Tugwell P, Wells GA, Simon LS.

J Rheumatol. 2019 Aug;46(8):1053-1058. doi: 10.3899/jrheum.181123. Epub 2019 Jan 15.

PMID:
30647191
23.

Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative.

Nielsen SM, Tugwell P, de Wit MPT, Boers M, Beaton DE, Woodworth TG, Escorpizo R, Shea B, Toupin-April K, Guillemin F, Strand V, Singh JA, Kloppenburg M, Furst DE, Wells GA, Smolen JS, Veselý R, Boonen A, Storgaard H, Voshaar M, March L, Christensen R; Contextual Factors Working Group.

J Rheumatol. 2019 Jan 15. pii: jrheum.181081. doi: 10.3899/jrheum.181081. [Epub ahead of print]

PMID:
30647174
24.

The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis.

Wechalekar MD, Najm A, Veale DJ, Strand V.

J Rheumatol. 2019 Jan 15. pii: jrheum.181062. doi: 10.3899/jrheum.181062. [Epub ahead of print]

PMID:
30647173
25.

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.

Curtis JR, Flake DD 2nd, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS.

Rheumatology (Oxford). 2018 Dec 24. doi: 10.1093/rheumatology/key367. [Epub ahead of print]

26.

Correction to: Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, de Bellefon LM, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 19;20(1):282. doi: 10.1186/s13075-018-1795-5.

27.

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Duffin KC, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2019 Aug;46(8):990-995. doi: 10.3899/jrheum.181077. Epub 2018 Dec 15.

PMID:
30554154
28.

Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial.

Strand V, Alemao E, Lehman T, Johnsen A, Banerjee S, Ahmad HA, Mease PJ.

Arthritis Res Ther. 2018 Dec 6;20(1):269. doi: 10.1186/s13075-018-1769-7.

29.

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.

Coates LC, Gladman DD, Nash P, FitzGerald O, Kavanaugh A, Kvien TK, Gossec L, Strand V, Rasouliyan L, Pricop L, Ding K, Jugl SM, Gaillez C; FUTURE 2 study group.

Arthritis Res Ther. 2018 Dec 7;20(1):272. doi: 10.1186/s13075-018-1773-y.

30.

Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Najm A, Le Goff B, Orr C, Thurlings R, Cañete JD, Humby F, Alivernini S, Manzo A, Just SA, Romão VC, Krenn V, Müller-Ladner U, Addimanda O, Tas SW, Stoenoiu M, Meric de Bellefon L, Durez P, Strand V, Wechalekar MD, Fonseca JE, Lauwerys B, Fearon U, Veale DJ; EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group.

Arthritis Res Ther. 2018 Dec 3;20(1):265. doi: 10.1186/s13075-018-1762-1. Erratum in: Arthritis Res Ther. 2018 Dec 19;20(1):282.

31.

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison.

Maksymowych WP, Strand V, Nash P, Yazici Y, Thom H, Hunger M, Kalyvas C, Gandhi KK, Porter B, Jugl SM.

Eur J Rheumatol. 2018 Dec;5(4):216-223. doi: 10.5152/eurjrheum.2018.18162. Epub 2018 Oct 30.

32.

Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.

Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S.

Arthritis Care Res (Hoboken). 2019 Jun;71(6):829-838. doi: 10.1002/acr.23788. Epub 2019 Apr 29.

33.

Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.

Kim AHJ, Strand V, Sen DP, Fu Q, Mathis NL, Schmidt MJ, Bruchas RR, Staten NR, Olson PK, Stiening CM, Atkinson JP.

Arthritis Rheumatol. 2019 Mar;71(3):420-430. doi: 10.1002/art.40747. Epub 2019 Jan 24.

34.

Classification and Outcome Measures for Psoriatic Arthritis.

Leung YY, Ogdie A, Orbai AM, Tillett W, Coates LC, Strand V, Mease P, Gladman DD.

Front Med (Lausanne). 2018 Sep 6;5:246. doi: 10.3389/fmed.2018.00246. eCollection 2018. Review.

35.

Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs.

Bodick N, Williamson T, Strand V, Senter B, Kelley S, Boyce R, Lightfoot-Dunn R.

Rheumatol Ther. 2018 Dec;5(2):475-498. doi: 10.1007/s40744-018-0125-3. Epub 2018 Sep 10.

36.

Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study.

Deodhar A, Conaghan PG, Kvien TK, Strand V, Sherif B, Porter B, Jugl SM, Gandhi KK; MEASURE 2 study group.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):260-269. Epub 2018 Jul 19.

PMID:
30148436
37.

Functional impairment measurement in psoriatic arthritis: Importance and challenges.

Mease P, Strand V, Gladman D.

Semin Arthritis Rheum. 2018 Dec;48(3):436-448. doi: 10.1016/j.semarthrit.2018.05.010. Epub 2018 May 23. Review.

38.

Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity.

Karpouzas GA, Strand V, Ormseth SR.

RMD Open. 2018 Jun 28;4(1):e000695. doi: 10.1136/rmdopen-2018-000695. eCollection 2018.

39.

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

Strand V, Michalska M, Birchwood C, Pei J, Tuckwell K, Finch R, Kivitz AJ, Smolen JS, Burmester GR.

RMD Open. 2018 Jun 17;4(1):e000602. doi: 10.1136/rmdopen-2017-000602. eCollection 2018.

40.

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1).

Gottlieb AB, Strand V, Kishimoto M, Mease P, Thaçi D, Birt J, Lee CH, Shuler CL, Lin CY, Gladman DD.

Rheumatology (Oxford). 2018 Oct 1;57(10):1777-1788. doi: 10.1093/rheumatology/key161.

41.

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.

Strand V, Gossec L, Proudfoot CWJ, Chen CI, Reaney M, Guillonneau S, Kimura T, van Adelsberg J, Lin Y, Mangan EK, van Hoogstraten H, Burmester GR.

Arthritis Res Ther. 2018 Jun 19;20(1):129. doi: 10.1186/s13075-018-1614-z.

42.

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.

McInnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, Pricop L, Jugl SM, Gandhi KK; FUTURE 2 Study Group.

Arthritis Res Ther. 2018 Jun 7;20(1):113. doi: 10.1186/s13075-018-1610-3.

43.

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.

PMID:
29858348
44.

A Pooled Analysis of Two Multicenter, Randomized Controlled Trials of a Single Intra-articular Injection of Gel-200 for Treatment of Osteoarthritis of the Knee.

Takamura J, Seo T, Strand V.

Clin Med Insights Arthritis Musculoskelet Disord. 2018 May 9;11:1179544118773068. doi: 10.1177/1179544118773068. eCollection 2018.

45.

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses.

Strand V, Kavanaugh A, Kivitz AJ, van der Heijde D, Kwok K, Akylbekova E, Soonasra A, Snyder M, Connell C, Bananis E, Smolen JS.

Rheumatol Ther. 2018 Dec;5(2):341-353. doi: 10.1007/s40744-018-0113-7. Epub 2018 May 14.

46.

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.

Strand V, Lee EB, Yazici Y, Dikranian A, Wilkinson B, Takiya L, Zang C, Bananis E, Bergman MJ.

Clin Rheumatol. 2018 Aug;37(8):2043-2053. doi: 10.1007/s10067-018-4077-3. Epub 2018 Apr 14.

47.

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.

Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, Simon LS, Strand V, Lipsky PE.

Arthritis Rheumatol. 2018 Sep;70(9):1450-1458. doi: 10.1002/art.40522. Epub 2018 Aug 3.

PMID:
29648686
49.

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.

Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

J Manag Care Spec Pharm. 2018 Apr;24(4):344-352. doi: 10.18553/jmcp.2018.24.4.344.

50.

Rheumatoid arthritis.

Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K.

Nat Rev Dis Primers. 2018 Feb 8;4:18001. doi: 10.1038/nrdp.2018.1. Review.

PMID:
29417936

Supplemental Content

Loading ...
Support Center